Synthetic small molecule inhibitors of Hh signaling as anti-cancer chemotherapeutics

Current Medicinal Chemistry

Volumn 22, Issue 35, 2015, Pages 4033-4057

  Maschinot, C A ^a   Pace, J R ^a   Hadden, M K ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Basal cell carcinoma; Gli; Hedgehog signaling; Medulloblastoma; Smoothened; Synthetic small molecules

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BMS 833923; BRD 6851; CILIOBREVIN A; CILIOBREVIN D; CMAP 7; CYTOPLASMIC DYNEIN; EGGMANONE; FN 1 8; GANT 58; GANT 61; GLASDEGIB; IMIQUIMOD; ITRACONAZOLE; MEBENDAZOLE; MICRORNA; ML 340; N (2 PYRIMIDINY AMINO)BENZAMIDE; NMDA 298 1; PYRVINIUM EMBONATE; ROBOTNIKIN; RU SKI 43; SONIDEGIB; TALADEGIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB; HIPPO PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN SERINE THREONINE KINASE;

ACUTE LEUKEMIA; ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CELLULAR DISTRIBUTION; DOSE RESPONSE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTIC FLAGELLUM; FOLLOW UP; HEDGEHOG SIGNALING; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84959504440     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150827093904     Document Type: Article

References (129)

1. Amakye, D.; Jagani, Z.; Dorsch, M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat. Med., 2013, 19, 1410-1422.
2. Briscoe, J.; Thérond, P. P. The mechanisms of hedgehog signaling and its roles in development and disease. Nat. Rev. Mol. Cell. Biol., 2013, 14, 416-429.
3. Trinh, T. N.; McLaughlin, E. A.; Gordon, C. P.; McCluskey, A. Hedgehog signaling pathway inhibitors as cancer suppressing agents. Med. Chem. Commun., 2014, 5, 117-133.
4. Gupta, S.; Takebe, N.; LoRusso, P. Targeting the Hedgehog pathway in cancer. Ther. Adv. Med. Oncol., 2010, 2, 237-250.
5. Rohatgi, R.; Milenkovic, L.; Scott, M. P. Patched1 regulates hedgehog signaling at the primary cilium. Science, 2007, 317, 372-376.
6. Nozama, Y. I.; Lin, C.; Chuang, P.-T. Hedgehog Signaling from the primary cilium to the nucleus: an emerging picture of ciliary localization, trafficking and transduction. Current Opin. Genetics Develop., 2013, 23, 429-437.
7. Milenkovic, L.; Weiss, L. E.; Yoon, J.; Roth, T. L.; Su, Y. S.; Sahl, S. J.; Scott, M. P.; Moerner, W. E. Singlemolecule imaging of Hedgehog pathway protein Smoothened in primary cilia revels binding events regulated by Patched1. Proc. Natl. Acad. Sci. USA, 2015, 112, 8320-8325.
8. Ling, G.; Ahmadian, A.; Persson, A.; Undén, A. B.; Afink, G.; Williams, C.; Uhlén, M.; Toftgård, R.; Lundenerg, J.; Pontén, F. Patched and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene, 2001, 20, 7770-7778.
9. Reifenberger, J.; Wolter, M.; Knobbe, C.B.; Köhler, B.; Schönicke, A.; Scharwächter, C.; Kumar, K.; Blaschke, B.; Ruzicka, T.; Reifenberger, G. Somatic mutations in the PTCH, SMOH, SUFUH, and TP53 genes in sporadic basal cell carcinoma. Br. J. Dermatol., 2005, 152, 43-51.
10. Raffel, C.; Jenkins, R. B.; Frederick, L.; Hebrink, D. Sporadic medulloblastomas contain PTCH mutations. Cancer Res., 1997, 57, 842-845.
11. Taylor, M. D.; Liu, L.; Raffel, C.; Hui, C. C.; Mainprize, T. G.; Zhang, X.; Agatep, R.; Chiappa, S.; Gao, L.; Lowrance, A.; Hao, A.; Goldstein, A. M.; Stavrou, T.; Scherer, S. W.; Dura, W. T.; Wainwright, B.; Squire, J. A.; Rutka, J. T.; Hogg, D. Mutations in SUFU predispose to medulloblastoma. Nat. Genet., 2002, 31, 306-310.
12. Tostar, U.; Malm, C. J.; Meis-Kindblom, J. M.; Kindblom, L. G.; Toftgård, R.; Undén, A. B. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol., 2006, 208, 17-25.
13. Zibat, A.; Missiaglia, E.; Rosenberger, A.; Pritchard-Jones, K.; Shipley, J.; Hahn, H.; Fulda, S. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene, 2010, 29, 6323-6330.
14. Buonamici, S.; Williams, J.; Morrissey, M.; Wang, A.; Guo, R.; Vattay, A.; Hsiao, K.; Yuan, J.; Green, J.; Ospina, B.; Yu, Q.; Ostrom, L.; Fordjour, P.; Anderson, D. L.; Monahan, J.E.; Kelleher, J. F.; Peukert, S.; Pan, S.; Wu, X.; Maira, S.-M.; Garcia-Echeverria, C.; Briggs, K. J.; Watkins, D. N.; Yao, Y.-M.; Lengauer, C.; Warmuth, M.; Sellers, W.R.; Dorsch, M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med., 2010, 2, 51ra70.
15. Northcott P.A.; Nakahara Y.; Wu X.C.; Feuk L.; Ellison D.W.; Croul S.; Mack S.; Kongkham P.N.; Peacock J.; Dubuc A.; Ra Y.S.; Zilberberg K.; Mcleod J.; Scherer S.W.; Rao J.S.; Eberhart C.G.; Grajkowska W.; Gillespie Y.; Lach B.; Grundy R.; Pollack I.F.; Hamilton R.L.; Van Meter T.; Carlotti C.G.; Boop F.; Bigner D.; Gilbertson R.J.; Rutka J.T.; Taylor M.D. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet., 2009. 41, 465-472.
16. Justilien, V.; Fields, A. P. Novel approaches for improved therapeutic targeting of hedgehog signaling in cancer stem cells. Clin. Cancer. Res., 2015, 21, 505-513.
17. Yang, L.; Xie, G.; Fan, Q.; Xie, J. Activation of the hedgehog- signaling pathway in human cancer and the clinical implications. Oncogene, 2010, 29, 469-481.
18. Ruat, M.; Hoch, L.; Faure, H.; Rognan, D. Targeting of smoothened for therapeutic gain. Trends Pharmacol. Sci., 2014, 34, 237-246.
19. Dlugosz, A.; Agrawal, S.; Kirkpatrick, P. Pipeline pioneers: vismodegib. Nat. Rev. Drug Discov., 2012, 11, 437-438.
20. Robarge K. D.; Brunton S. A.; Castanedo G. M.; Cui, Y.; Dina, M. S.; Goldsmith, R.; Sould, S. E.; Guichert, O.; Gunzner, J. L.; Halladay, J.; Jia, W.; Khojasteh, C.; Koehler, M. F.; Kotkow, K.; La, H.; Lalonde, R. L.; Lau, K.; Lee, L.; Marshall, D.; Marsters, J. C.; Murray, L. J.; Qian, C.; Rubin, L. L.; Salphati, L.; Stanley, M. S.; Stibbard, J. H.; Sutherlin, D. P.; Ubhayaker, S.; Wang, S.; Wong, S.; Xie, M. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett., 2009, 19, 5576-5581.
21. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/home (accessed May 8, 2015).
22. Pan, S.; Wu, X.; Jiang, J. Gao, W.; Wan, Y.; Cheng, D.; Han, D.; Liu, J.; Englund, N. P.; Wang, Y.; Peukert, S.; Miller-Moslin, K.; Yuan, J.; Guo, R.; Matsumoto, M.; Vattay, A.; Jiang, Y.; Tsao, J.; Sun, F.; Pferdekamper, A. C.; Dodd, S.; Tuntland, T.; Maniara, W.; Kelleher, J. F., III; Yao, Y.; Warmuth, M.; Williams, J.; Dorsch, M. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med. Chem. Lett., 2010, 1, 130-134.
23. Munchhof, M. J.; Li, Q.; Shavna, A.; Borzillo, G. V.; Boyden, T. L.; Jones, C. S.; LaGreca, S. D.; Martinez-Alsina, L.; Patel, N.; Pelletier, K.; Reiter, L. A.; Robbins, M. D.; Tkalcevic, G. T. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med. Chem. Lett., 2012, 3, 106-111.
24. Gendreau, S. B.; Hawkins, D.; Ho, C.-H.; Lewin, A.; Lin, T.; Merchant, A.; Rowley, R. B.; Wang, Q.; Matsui, W.; Fargnoli, J. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Mol. Cancer Ther., 2009, 8, B192.
25. Bender M. H.; Hipskind P. A.; Capen A. R.; Cockman, M.; Credille, K. M.; Gao, H.; Bastian, J. A.; Clay, J. M.; Lobb, K. L.; Sall, D. J.; Thompson, M. L.; Wilson, T.; Wishart, G. N.; Patel, B. K. R. Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Res., 2011, 71, 2819.
26. Xin, M. Hedgehog inhibitors: a patent review (2013- present). Expert Opin. Ther. Patents, 2015, 25(5), 549-565.
27. Banerjee, U.; Hadden, M. K. Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies. Expert Opin. Drug Discov., 2014, 9, 751-771.
28. Rudin, C. M.; Hann, C. L.; Laterra, J.; Yauch, R. L.; Callahan, C. A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S. E.; Coleman, B.; LoRusso, P. M.; Von Hoff, D. D.; de Sauvage, F. J.; Low, J. A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med., 2009, 361, 1173-1178.
29. Yauch R. L.; Dijkgraaf, G. J.; Alicke, B.; Januario, T.; Ahn, C. P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C. A.; Tang, T.; Bazan, J. F.; Kan, Z. Seshagiiri, S.; Hann, C. L.; Gould, S. E.; Low, J. A.; Rudin, C. M.; de Sauvage, F. J. Smoothened mutation confers resistance to a hed gehog pathway inhibitor in medulloblastoma. Science, 2009, 326, 572-574.
30. Dijkgraaf, G. J. P.; Alicke, B.; Weinmann, L.; Januario, T.; West, K.; Modrusan, Z.; Burdick, D.; Goldsmith, R.; Robarge, K.; Sutherlin, D.; Scales, S. J.; Gould, S. E.; Yauch, R. L.; de Sauvage, F. J. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res., 2011, 71, 435-444.
31. Pricl, S.; Cartelazzi, B.; Col, V. D.; Marson, D.; Laurini, E.; Fermeglia, M.; Licitra, L.; Pilotti, S.; Bossi, P.; Perrone, F. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol. Oncol., 2015, 9, 389-397.
32. Sharpe, H. J.; Pau, G.; Dijkgraaf, G. J.; Basses-Seguin, N.; Modrusan, Z.; Januario, T.; Tsui, V.; Durham, A. B.; Dlugosz, A. A.; Haverty, P. M.; Bourgon, R.; Tang, J. Y.; Sarin, K. Y.; Dirix, L.; Fisher, D. C.; Rudin, C. M.; Sofen, H.; Migden, M. R.; Yauch, R. L.; de Sauvage, F. J. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell, 2015, 27, 327-341.
33. Atwood, S. X.; Sarin, K. Y.; Whitson, R. J.; Li, J. R.; Kim, G.; Rezaee, M.; Ally, M. S.; Kim, J.; Yao, C.; Chang, A. L. S.; Oro, A. E.; Tang, J. Y. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell, 2015, 27, 342-353.
34. Lee, M. J.; Hatton, B. A.; Villavicencio, E. H.; Khanna, P. C.; Friedman, S. D.; Ditzler, S.; Pullar, B.; Robison, K.; White, K. F.; Tunkey, C.; LeBlanc, M.; Randolph- Habecker, J.; Knoblaugh, S. E.; Hansen, S.; Richards, A.; Wainwright, B. J.; McGovern, K.; Olson, J. M. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc. Natl. Acad. Sci. USA, 2012, 109, 7859-7864.
35. Wang, Y.; Ding, Q.; Yen, C. J.; Xia, W.; Izzo, J. G.; Lang, J. Y.; Li, C. W.; Hsu, J. L.; Miller, S. A.; Wang, X.; Lee, D. F.; Hsu, J. M.; Huo, L.; Labaff, A. M.; Liu, D.; Huang, T. H.; Lai, C. C.; Tsai, F. J.; Chang, W. C.; Chen, C. H.; Wu, T. T.; Buttar, N. S.; Wang, K. K.; Wu, Y.; Wang, H.; Ajani, J.; Hung, M. C. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer Cell, 2012, 21, 374-387.
36. Das, S.; Samant, R. S.; Shevde, L. A. Nonclassical activation of hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting hedgehog inhibition. J. Biol. Chem., 2013, 288, 11824-11833.
37. Peukert, S.; He, F.; Dai, M.; Zhang, R.; Sun, Y.; Miller- Moslin, K.; McEwan, M.; Lagu, B.; Wang, K.; Yusuff, N.; Bourret, A.; Ramamurthy, A.; Maniara, W.; Amaral, A.; Vattay, A.; Wang, A.; Guo, R.; Yuan, J.; Green, J.; Williams, J.; Buonamici, S.; Kelleher, J. F.; Dorsch, M. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem, 2013, 8, 1261-1265.
38. Tao, H.; Jin, Q.; Koo, D.; Liao, X.; Englund, N. P.; Wang, Y.; Ramamurthy, A.; Schultz, P. G.; Dorsch, M.; Kelleher, J.; Wu, X. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem. Biol., 2011, 18, 432-437.
39. Fan, C.; Chen, B.; Franco, I.; Lu, J.; Shi, H.; Wei, S.; Wang, C.; Wu, X.; Tang, W.; Roth, M. G.; Williams, N. S.; Hirsch, E.; Chen, C.; Lum, L. The hedgehog pathway effector of smoothened exhibits signaling competency in the absence of ciliary accumulation. Chem. Biol., 2014, 21, 1680-1689.
40. Manetti, F.; Faure, H.; Roudaut, H.; Gorojankina, T.; Traiffort, E.; Schoenfelder, A.; Mann, A.; Solinas, A.; Taddei, M.; Ruat, M. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family as smoothened antagonists. Mol. Pharmacol., 2010, 78, 658-665.
41. Solinas, A.; Faure, H.; Roudaut, H.; Traiffort, E.; Schoenfelder, A.; Mann, A.; Manetti, F.; Taddei, M.; Ruat, M. Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. J. Med. Chem., 2012, 55, 1559-1571.
42. Hoch, L.; Faure, H.; Roudaut, H.; Schoenfelder, A.; Mann, A.; Girard, N.; Bihannic, L.; Ayrault, O.; Petricci, E.; Taddei, M.; Rognan, D.; Ruat, M. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J., 2015, 29, 1-13.
43. Roudaut, H.; Traiffort, E.; Gorojankina, T.; Vincent, L.; Faure, H.; Schoenfelder, A.; Mann, A.; Manetti, F.; Solinas, A.; Taddei, M.; Ruat, M. Identification and mechanism of action of the acylguanidine MRT-83, a novel potent smoothened antagonist. Mol. Pharmacol., 2011. 79, 452-460.
44. Malancona, S.; Altamura, S.; Filocamo, G.; Kinzel, O.; Hernando, J. I.; Rowley, M.; Scarpelli, R.; Steinkühler, C.; Jones, P. Identification of MK-5710 ((8aS)-8a-methyl-1,3- dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1Hpyrazol- 5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)- carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 1. Bioorg. Med. Chem. Lett., 2011, 21, 4422-4428.
45. Kinzel, O.; Alfieri, A.; Altamura, S.; Brunetti, M.; Bufali, S.; Colaceci, F.; Ferrigno, F.; Filocamo, G.; Fonsi, M.; Malancona, S.; Hernando, J. I.; Monteagudo, E.; Orsale, M. V.; Palumbi, M. C.; Pucci, V.; Rowley, M.; Sasso, R.; Scarpelli, R.; Steinkühler, C.; Jones, P. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenyl cyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimidazo[ 1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 2. Bioorg. Med. Chem. Lett., 2011, 21, 4429-4435.
46. Ontoria, J. M.; Bufi, L. L.; Torrisi, C.; Bresciani, A.; Giomini, C.; Rowley, M.; Serafini, S.; Bin, H.; Hao, W.; Steinkühler, C.; Jones, P. Identification of a series of 4-[3- (quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 5274-5282.
47. Muraglia, E.; Ontoria, J. M.; Branca, D.; Dessole, G.; Bresciani, A.; Fonsi, M.; Giuliano, C.; Llauger Bufi, L.; Monteagudo, E.; Palumbi, M. C.; Torrisi, C.; Rowley, M.; Steinkühler, C.; Jones, P. N-(2-alkylaminoethyl)-4-(1,2,4- oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothened antagonists. Bioorg. Med. Chem. Lett., 2011, 21, 5283-5288.
48. Ishii, T.; Shimizu, Y.; Nakashima, K.; Kondo, S.; Ogawa, K.; Sasaki, S.; Matsui, H. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against vismodegib- resistant smoothened mutant. Eur. J. Pharmacol., 2014, 723, 305-313.
49. Strand, M. F.; Wilson, S. R.; Dembinski, J. L.; Holsworth, D. D.; Khvat, A.; Okun, I.; Petersen, D.; Krauss, S. A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. PLoS One, 2011, 6, e19904.
50. Ghannoum, M. A.; Rice, L. B. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev., 1999, 12, 501-517.
51. Kim, J.; Tang, J. Y.; Gong, R.; Kim, J.; Lee, J. J.; Clemons, K. V.; Chong, C. R.; Chang, K. S.; Fereshteh, M.; Gardner, D.; Reya, T.; Liu, J. O.; Epstein, E. H.; Stevens, D. A.; Beachy, P. A. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell, 2010, 17, 388-399.
52. Kim, J.; Aftab, B. T.; Tang, J. Y.; Kim, D.; Lee, A. H.; Rezaee, M.; Kim, J.; Chen, B.; King, E. M.; Borodovsky, A.; Riggins, G. J.; Epstein, E. H.; Beachy, P. A.; Rudin, C. M. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell, 2013, 23, 23-34.
53. Kim, D. J.; Kim, J.; Spaunhurst, K.; Montoya, J.; Khodosh, R.; Chandra, K.; Fu, T.; Gilliam, A.; Molgo, M.; Beachy, P. A.; Tang, J. Y. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J. Clin. Oncol., 2014, 32, 745-751.
54. Shi, W.; Nacev, B. A.; Aftab, B. T.; Head, S.; Rudin, C. M.; Liu, J. O. Itraconazole side chain analogues: structureactivity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. J. Med. Chem., 2011, 54, 7363-7374.
55. Chong, C. R.; Xu, J.; Lu, J.; Bhat, S.; Sullivan, D. J.; Liu, J. O. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem. Biol., 2007, 2, 263-270.
56. Shi, W.; Nacev, B. A.; Bhat, S.; Liu, J. O. Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of traconazole. ACS Med. Chem. Lett., 2010, 1, 155-159.
57. Nacev, B. A.; Grassi, P.; Dell, A.; Haslam, S. M.; Liu, J. O. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J. Biol. Chem., 2011, 286, 44045-44056.
58. Wang, Y.; Arvanites, A. C.; Davidow, L.; Blanchard, J.; Lam. K.; Yoo, J. W.; Coy, S.; Rubin, L. L.; McMahon, A. P. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem. Biol., 2012, 7, 1040-1048.
59. Wu, V. M.; Chen, S. C.; Arkin, M. R.; Reiter, J. F. Small molecule inhibitors of smoothened ciliary localization and ciliogenesis. Proc. Natl. Acad. Sci. USA, 2012, 109, 13644-13649.
60. Xin, M.; Wen, J.; Tang, F.; Tu, C.; Shen, H.; Zhao, X. The discovery of novel N-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 6777-6783.
61. Xin, M.; Wen, J.; Tang, F.; Tu, C.; Huang, W.; Shen, H.; Zhao, X.; Cheng, L.; Wang, M.; Zhang, L. Synthesis and evaluation of 4-(2-pyrimidinylamino)benzamides inhibitors of hedgehog signaling pathway. Bioorg. Med. Chem. Lett., 2014, 24, 983-988.
62. Xin, M.; Zhang, L.; Tang, F.; Tu, C.; Wen, J.; Zhao, X.; Liu, Z.; Cheng, L.; Shen, H. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors. Bioorg. Med. Chem., 2014, 22, 1429-1440.
63. Wu, T.; Wang, D.; Xiang, P.; Zhang, J.; Sang, Y.; Lin, H.; Chen, J.; Xie, G.; Song, H.; Zhao, Y.; Xie, Y. Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists. Bioorg. Med. Chem., 2014, 24, 1426-1431.
64. Sun, C.; Li, Y.; Shi, A.; Zhang, J.; Li, Y.; Zhao, M.; Zhang, L.; Zheng, H.; Meng, Y.; Ding, H.; Song, H. Synthesis and evaluation of novel N-3-benzimidazolephenylbisamide derivatives for antiproliferative and hedgehog pathway inhibitor activity. Med. Chem. Commun., 2015, In Press.
65. Canettieri, G.; Marcotullio, L. D.; Greco, A.; Coni, S.; Antonucci, L.; Infante, P.; Pietrosanti, L.; De Smaele, E.; Ferretti, E.; Miele, E.; Pelloni, M.; Simone, G. D.; Pedone, E. M.; Gallinari, P.; Giorgi, A.; Steinkühler, C.; Vitagliano, L.; Pedone, C.; Schinin, M. E.; Screpanti, I.; Gulino, A. Histone deacetylase and cullin3-RENKCTD11 ubiquitin ligase interplay regulates hedgehog signaling through Gli acetylation. Nat. Cell Biol., 2010, 12, 132-142.
66. Zhao, J.; Quan, H.; Xie, C.; Lou, L. NL-103, a novel dualtargeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharm. Res. Per., 2014, 2, 1-13.
67. Lu, W.; Geng, D.; Sun, Z.; Yang, Z.; Ma, H.; Zheng, J.; Zhang, X. Scaffold hopping approach to a new series of smoothened antagonists. Bioorg. Med. Chem. Lett., 2014, 24, 2300-2304.
68. Ma, H.; Lu, W.; Sun, Z.; Luo, L.; Geng, D.; Yang, Z.; Li, E.; Zheng, J.; Wang, M.; Zhang, H.; Yang, S.; Zhang, X. Design, synthesis, and structure-activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists. Eur. J. Med. Chem., 2015, 89, 721-732.
69. Betti, M.; Castagnoli, G.; Panico, A.; Sanna Coccone, S.; Wiedenau, P. Development of a scalable route to the SMO receptor antagonist SEN794. Org. Process Res. Dev., 2012, 16, 1739-1745.
70. Nair, S. K.; Planken, S. P. Pyridine-2-derivatives as Smoothened Receptor Modulators, 2012, WO2012052948.
71. Rohner, A.; Spilker, M. E.; Lam, J. L.; Pascual, B.; Bartkowski, D.; Li, Q. J.; Yang, A. H.; Stevens, G.; Xu, M.; Wells, P. A.; Planken, S.; Nair, S.; Sun, S.Effective targeting of hedgehog signaling in a medulloblastoma model with PF-527457, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol. Cancer Ther., 2012, 11, 57-65.
72. Nedelcu, D.; Liu, J.; Xu, Y.; Jao, C.; Salic, A. Oxysterol binding to the extracellular domain of smoothened in hedgehog signaling. Nat. Chem. Biol., 2013, 9, 557-64.
73. Wang, Y.; Davidow, L.; Arvanites, A. C.; Blanchard, J.; Lam, K.; Xu, K.; Oza, A.; Yoo, J. S.; Ng, J. M.; Curran, T.; Rubin, L. L.; McMahon, A. P. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem. Biol., 2012, 19, 972-82.
74. Nachtergaele, S.; Whalen, D.M.; Mydock, L.K.; Zhao, Z.; Malinauskas, T.; Krishnan. K.; Ingham, P. W.; Covey, D. F.; Siebold, C.; Rohatgi, R. Structure and function of the smoothened extracellular domain in vertebrate hedgehog signaling. Elife, 2013, 2, e01340.
75. Wang, C.; Wu, H.; Katritch, V.; Han, G. W.; Huang, X. P.; Liu W.; Siu, F. Y.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human smoothened receptor bound to an antitumour agent. Nature, 2013, 497, 338-343.
76. Weierstall, U.; James, D.; Wang, C.; White, T.A.; Wang, D.; Liu, W.; spence, J. C.; bruce doak, R.; Nelson, G.; Fromme, P.; Fromme, R.; Grotkohann, I.; Kupitz, C.; Zatsepin, N. A.; Liu, H.; Basu, S.; Wacker, D.; Han, G. W.; Katritch, V.; Boutet, S.; Messerschmidt, M.; Williams, G. J.; Koglin, J. E.; Marvin Seibert, M.; Klinker, M.; Gati, C.; Shoeman, R. L.; Barty, A.; Chapman, H. N.; Kirian, R. A.; Beyerlein, K. R.; Stevens, R. C.; Li, D.; Shah, S. T.; Howe, N.; Caffrey, M.; Cherezov, V. Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. Nat. Commun., 2014, 5, 3309.
77. Wang, C.; Wu, H.; Evron, T.; Vardy, E.; Han, G. W.; Huang, X.-P.; Hufeisen, S. J.; Mangano, T. J.; Urban, D. J.; Katritch, V.; Cherezov, V.; Caron, M. G.; Roth, B. L.; Stevens, R. C. Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs. Nature Commun., 2014, 5, 4355.
78. Myers, B.R.; Sever, N.; Chong ,Y. C.; Kim, J.; Belani, J. D.; Rychnovsky, S.; Bazan, J. F.; Beachy, P. A. Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. Dev. Cell., 2013, 26, 346-57.
79. Rana, R.; Carroll, C.E.; Lee, H.; Bao, J.; Marada, S.; Grace, C. R.; guibao, C. D.; Ogden, S. K.; Zheng, J. J. Structural insights into the role of the smoothened cysteine-rich domain in hedgehog signalling. Nat. Commun., 2013, 4, 2965.
80. Chamoun, Z.; Mann, R. K.; Nellen, D.; von Kessler, D. P.; Bellotto, M.; Beachy, P. A.; Basler, K. Skinny hedgehog, an acyltransferase required for palmitoylation and activity of the hedgehog signal. Science, 2001, 293, 2080-2084.
81. Petrova, E.; Rios-Esteves, J.; Ouerfelli, O.; Glickman, J. F.; Resh, M. D. Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling. Nat. Chem. Biol., 2013, 9, 247-249.
82. Stanton, B. Z.; Peng, L. F.; Maloof, N.; Nakai, K.; Wang, X.; Duffner, J. L.; Taveras, K. M.; Hyman, J. M.; Lee, S. W.; Koehler, A. N.; Chen, J. K.; Fox, J. L.; Mandinova, A.; Schreiber, S. L. A small molecule that binds hedgehog and blocks its signaling in human cells. Nat. Chem. Biol., 2009, 5, 154-156.
83. Dockendorff, C.; Nagiec, M. M.; Weiwer, M.; Buhrlage, S.; Ting. A.; Nag, P. P.; Germain, A.; Kim, H. J.; Youngsaye, W.; Scherer, C.; Bennion, M.; Xue, L.; Stanton, B. Z.; Lewis, T. A.; Macpherson, L.; Palmer, M.; Foley, M. A.; Perez, J. R.; Schreiber, S. L. Macrocyclic hedgehog pathway inhibitors: Optimization of cellular activity and mode of action studies. ACS Med. Chem. Lett., 2012, 3, 808-813.
84. Hwang, S.; Thangapandian, S.; Lee, Y.; Sakkiah, S.; John, S.; Lee, K. W. Discovery and evaluation of potential sonic hedgehog signaling pathway inhibitors using pharmacophore modeling and molecular dynamics simulations. J. Bioinf. Comput. Biol., 2011, 9 (Suppl 1), 15-35.
85. Hwang, S.; Thangapandian, S.; Lee, K. W. Molecular dynamics simulations of sonic hedgehog-receptor and inhibitor complexes and their applications for potential anticancer agent discovery. PLoS One, 2013, 9, e68271.
86. Lauth, M.; Bergström, Å.; Shimokawa, T.; Toftgárd, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA, 2007, 104, 8455-8460.
87. Shi, T.; Mazumdar, T.; Devecchio, J.; Duan, Z.-H.; Agyeman, A.; Aziz, M.; Houghton, J. A. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One, 2010, 5, e13054.
88. Huang, L.; Walter, V.; Hayes, D.N.; Onaitis, M. Hedgehog- GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin. Cancer Res., 2014, 20, 1566-1575.
89. Fu, J.; Rodova, M.; Roy, S. K.; Sharma, J.; Singh, K. P.; Srivastava, R. K.; Shankar, S. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett., 2013, 330, 22-32.
90. Agyeman, A.; Jha, B. K.; Mazumdar, T.; Houghton, J.A. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget, 2014, 5, 4492-4503.
91. Stecca, B.; Ruiz, I. A. A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non- HEDGEHOG signals. J. Mol. Cell. Biol., 2010, 2, 84-95.
92. Hou, X.; Chen, X.; Zhang, P.; Fan, Y.; Ma, A.; Pang, T.; Song, Z.; Jin, Y.; Hao, W.; Liu, F.; Wang, W.; Wang, Y. Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells. Biochimie, 2014, 101, 50-59.
93. Infante, P.; Mori, M.; Alfonsi, R.; Ghirga, F.; Aiello, F.; Toscano, S.; Ingallina, C.; Siler, M.; Cucchi, D.; Po, A.; Miele, E.; D'Amico, D.; Canettieri, G.; De Smaele, E.; Ferretti, E.; Screpanti, I.; Barretta, G. U.; Botta, M.; Botta, B.; Gulino, A.; Di Marcotullio, L. Gli/DnA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J., 2015, 34, 200-217.
94. Ardecky, R.; Magnuson, G. K.; Zou, J.; Ganji, S. R.; Brown, B.; Ngo, T.; Lee, J.; Zeng, F-Y.; Sun, Q.; Stonich, D.; Salaniwal, S.; Sakata, T.; Rack, P. G.; Casabar, J. K. T.; Mangravita-Novo, A.; Smith, L. H.; Sergienko, E.; Chung, T. D. Y.; Pinkerton, A. B.; Pass, I.; Chen, J. K. "Smallmolecule antagonists of Gli function." Probe Reports from the NIH Molecular Libraries Program (Internet). Bethesda (MD): National Center for Biotechnology Information (US); 2010-2012 Dec 17.
95. Bosco-Clément, G.; Zhang, F.; Chen, Z.; Zhou, H. M.; Li, H.; Mikami, I.; Yagui-Beltran, A.; Lui, N.; Do, H. T.; cheng, T.; Tseng, H. H.; Choi, H.; Fang, L. T.; Kim, I. J.; Yue, D.; Wang, C.; Zheng, Q.; Fujii, N.; Mann, M.; Jablons, D. M.; He, B. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene, 2014, 33, 2087-2097.
96. The Regents of the University of California. Targeting Gli proteins in human cancer by small molecules. WO2014116651; 2014.
97. Mahindroo, N.; Connelly, M.C.; Punchihewa, C.; Kimura, H.; Smeltzer, M. P.; Wu, S.; Fujii, N. Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma associated oncogene homologue 1 (Gli1) mediated transcription. J. Med. Chem., 2009, 52, 4277-4287.
98. Müller, S.; Knapp, S. Discovery of BET bromodomain inhibitors and their role in target validation. Med. Chem. Commun., 2014, 5, 288-296.
99. Gallenkamp, D.; Gelato, K. A.; Haendler, B.; Weinmann, H. Bromodomains and their pharmacological inhibitors. ChemMedChem, 2014, 9, 438-464.
100. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.: Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains. Nature, 2010, 468, 1067-1073.
101. Tang, Y.; Gholamin, S.; Schubert, S.; Willardson, M. I.; Lee, A.; Bandopadhayay, P.; Bergthold, G.; Masoud, S.; Nguyen, B.; Vue, N.; Balansay, B.; Yu, F.; Oh, S.; Woo, P.; Chen, S.; Ponnuswami, A.; Monje, M.; Atwood, S. X.; Whitson, R. J.; Mitra, S.; Chesier, S. H.; Qi, J.; Beroukhim, R.; Tang, J. Y. Wechsler-Reya, R.; Oro, A. E.; Link, B. A.; Bradner, J. E.; Cho, Y-J. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med., 2014, 20, 732-740.
102. Long, J.; Li, B.; Rodriguez-Blanco, J.; Pastori, C.; Volmar, C-H.; Wahlstedt, C.; Capobianco, A.; Bai, F.; Pei, X-H.; Ayad, N. G.; Robbins, D. J. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened to abrogate the growth of Hedgehog driven cancers. J. Biol. Chem., 2014, 289, 35494-35502.
103. Larsen, A. R.; Bai, R.; Chung, J. H.; Borodovsky, A.; Rudin, C. M.; Riggins, G. J.; Bunz, F. Repurposing the antihelmintic mebendazole as a hedgehog Inhibitor. Mol. Cancer Ther., 2015, 14, 3-13.
104. Hyman, J. M.; Firestone, A. J.; Heine, V. M.; Zhao, Y.; Ocasio, C. A.; Han, K.; Sun, M.; Rack, P. G.; Sinha, S.; Wu, J. J.; Solow-Cordero, D. E.; Jiang, J.; Rowitch, D. H.; Chen, J. K. Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade. Proc. Natl. Acad. Sci. USA, 2009, 106, 14132-14137.
105. Firestone, A. J.; Weinger, J. S.; Maldonado, M.; Barlan, K.; Langston, L. D.; O'Donnell, M.; Gelfand, V. I.; Kapoor, T. M.; Chen, J. K. Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature, 2012, 484, 125-129.
106. Williams, C. H.; Hempel, J. E.; Hao, J.; Frist, A. Y.; Williams, M. M.; Fleming, J. T.; Sulikowski, G. A.; Cooper, M. K. Chiang, C.; Hong, C. C. An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition. Cell Rep., 2015, 11, 43-50.
107. Price, M.A. CKI, there's more than one: casein kinase I family members in Wnt and hedgehog signaling. Genes Devlop., 2006, 20, 399-410.
108. Thorne, C. A.; Hanson, A. J.; Schneider, J.; Tahinci, E.; Orton, D.; Cselenyi, C. S. Jernigan, K. K.; Meyers, K. C.; Hang, B. I.; Waterson, A. G.; Kim, K.; Melancon, B.; Ghidu, V. P.; Sulikowski, G. A.; LaFleur, B.; Salic, A.; Lee, L. A.; Miller, D. M.; Lee, E. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1. Nat. Chem. Biol., 2010, 6, 829-836.
109. Lum, L.; Yao, S.; Mozer, B.; Rovescalli, A.; Von Kessler, D.; Nirenberg, M.; Beachy, P. A. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science, 2003, 299, 2039-2045.
110. Li, B.; Fei, D. L.; Flaveny, C. A.; Dahmane, N.; Baubet, V.; Wang, Z.; Bai, F.; Pei, X-H.; Rodriquez-Blanco, J.; Hang, B.; Orton, D.; Han, L.; Wang, B.; Capobianco, A. J.; Lee, E.; Robbins, D. J. Pyrvinium attenuates hedgehog signaling downstream of smoothened. Cancer Res., 2014, 74, 4811-4821.
111. Trincavelli, M. L.; Daniele, S.; Martini, C. Adenosine receptors: What we know and what we are learning. Curr. Top. Med. Chem., 2010, 10, 860-877.
112. Mondal, B. C.; Mukherjee, T.; Mandal, L.; Evans, C. J.; Sinenko, S. A.; Martinez-Agosto, J. A.; Banerjee, U. Interaction between differentiating cell- and niche-derived signals in hematopoietic progenitor maintenance. Cell, 2011, 147, 1589-1600.
113. Schön, M. P.; Schön M.; Klotz, K. N. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8- independent fashion. J. Invest. Dermatol., 2006, 126, 1338-1347.
114. Wolff, F.; Loipetzberger, A.; Gruber, W.; Esterbauer, H.; Aberger, F.; Frischauf, A.M. Imiquimod directly inhibits hedgehog signaling by stimulating adenosine receptor/ protein kinase A-mediated GLI phosphorylation. Oncogene, 2013, 32, 5574-5581.
115. Bassilana, F.; Carlson, A.; DaSilva, J. A.; Grosshans, B.; Vidal, S.; Beck, V.; Wilmeringwetter, B.; Llamas, L. A.; Showalter, T. B.; Rigollier, P.; Bourret, A.; Ramamurthy, A.; Wu, X.; Harbinski, F.; Plonsky, S.; Lee, L.; Ruffner, H.; Grandi, P.; Schirle, M.; Jenkins, J.; Sailer, A. W.; Bouwmeester, T.; Porter, J. A.; Myer, V.; Finan, P. M.; Tallarico, J. A.; Kelleher III, J. F.; Seuwen, K.; Jain, R. K.; Luchansky, S. J. Target identification for a hedgehog pathway inhibitor reveals the receptor GPR39. Nat. Chem. Biol., 2014, 10, 343-349.
116. Garcia-Castro, M.; Kremer, L.; Reinkemeier, C. D.; Unkelbach, C.; Strohmann, C.; Ziegler, S.; Ostermann, C.; Kumar, K. De novo branching cascades for structural and functional diversity in small molecules. Nature Commun., 2015, 1-13.
117. Schaefer, G. I.; Perez, J. R.; Duvall, J.R.; Stanton, B.Z.; Shamji, A.F.; Schreiber, S. L. Discovery of small-molecule modulators of the sonic hedgehog pathway. J. Am. Chem. Soc., 2013, 135, 9675-9680.
118. Ericson, J.; Morton, S.; Kawakami, A.; Roelink, H.; Jessell, T.M. Two critical periods of sonic hedgehog signaling required for the specification of motor neuron identity. Cell., 1996, 87, 661-673.
119. Maun, H. R.; Wen, X.; Lingel, A.; de Sauvage, F. J.; Lazarus, R. A.; Scales, S. J. Hymowitz, S. G. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J. Biol. Chem., 2010, 285, 26570-80.
120. Yauch, R. L.; Gould, S. E.; Scales, S. J.; Tang, T.; Tian, H.; Ahn, C. P.; Marshall, D.; Fu, L.; Januario, T.; Kallop, D.; Nannini-Pepe, M.; Kotkow, K.; Marsters, J. C.; Rubin, L. L.; de Sauvage, F. J. A paracrine requirement for hedgehog signalling in cancer. Nature, 2008, 455, 406-410.
121. O'Toole, S. A.; Machalek, D. A.; Shearer, R. F.; Millar, E. K.; Nair, R.; Schofield, P.; McLeod, D.; Cooper, C. L.; McNeil, C. M.; McFarland, A.; Nguyen, A.; Ormandy, C. J.; Qiu, M. R.; Rabinovich, B.; Martelotto, L. G.; Vu, D.; Hannigan, G. E.; Musgrove, E. A.; Christ, D.; Sutherland, R. L.; Watkins, D. N.; Swarbrick, A.; Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res., 2011, 71, 4002-4014.
122. Chang, Q.; Foltz, W.D.; Chaudary, N.; Hill, R. P.; Hedley, D. W. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. Int. J. Cancer, 2013, 133, 225-234.
123. Michaud, N. R.; Wang, Y.; McEachern K. A.; Jordan, J. J.; Mazzola, A. M.; Hernandz, A.; Jalla, S.; Chesebrough, J. W.; Hynes, M. J.; Belmonte, M. A.; Wang, L.; Kang, J. S.; Jovanovic, J.; Laing, N.; Jenkins, D. W.; Hurt, E.; Liang, M.; Frantz, C.; Hollingsworth, R. E.; Simeone, D. M.; Blakey, D. C.; Bedian, V. Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Mol. Cancer Ther., 2014, 13, 386-398.
124. Schmidt, M. F. Drug target miRNAs: chances and challenges. Trends Biotech., 2014, 32, 578-585.
125. Du, W.; Liu, X.; Chen, L.; Dou, Z.; Lei, X.; Chang, L.; Cai, J.; Cui, Y.; Yang, D.; Sun, Y.; Li, Y.; Jiang, C. Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. Neuro-Oncology, 2015, 17, 243-253.
126. Jiang, Z.; Cushing, L.; Ai, X.; Lu, J. miR-326 is downstream of sonic hedgehog signaling and regulates the expression of Gli2 and smoothened. Am. J. Respir. Cell Mol. Biol., 2014, 51, 273-283.
127. Kumar, V.; Mondal, G.; Slavik, P.; Rachagani, S.; Batra, S.K.; Mahato, R.I. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Mol. Pharm., 2015, 12, 1289-1298.
128. Gu, W.; Shou, J.; Gu, S.; Sun, B.; Che, X. Identifying hedgehog signaling specific MicroRNAs in glioblastomas. Int. J. Med. Sci., 2014, 11, 488-493.
129. Ferretti, E.; De Smaele, E.; Miele, E.; Laneve, P.; Po, A.; Pelloni, M.; Paganelli, A.; Di Marcotullio, L.; Caffarelli, E.; Screpanti, I.; Bozzoni, I.; Gulino, A. Concerted microRNA control of Hedgehog signaling in cerebellar neuronal progenitor and tumour cells. EMBO J., 2008, 27, 2616-2627.